CNBCLean R·
West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
Since CNBC highlighted the stock's attractive valuation in August, shares have gained around 20%. Why we expect more upside ahead.
Read at CNBC →
Business · 1 sources covering this
West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
Since CNBC highlighted the stock's attractive valuation in August, shares have gained around 20%. Why we expect more upside ahead.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/16b394c540abdf3bb44ce0ec7765d0bb5eefbab2" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="West Pharma earnings show it's more than a GLP-1 play. Why we see more upside"></iframe>
